<DOC>
	<DOCNO>NCT00471835</DOCNO>
	<brief_summary>RATIONALE : Stereotactic body radiation therapy may able send x-ray directly tumor cause less damage normal tissue . PURPOSE : This phase I/II trial study side effect best dose stereotactic body radiation therapy see well work treat patient stage I stage II non-small cell lung cancer .</brief_summary>
	<brief_title>Stereotactic Body Radiation Therapy Treating Patients With Stage I Stage II Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose hypofractionated stereotactic body radiotherapy ( SBRT ) central lung region ( peri-mediastinum ) patient stage I II non-small cell lung cancer . ( Phase I ) - Determine local control time local progression patient treat regimen . ( Phase II ) - Evaluate ability peak standardize uptake value ( SUV ) fludeoxyglucose F 18 ( FDG ) -PET scan , obtain shortly SBRT ( post-treatment ) , predict local control time progression patient . Secondary - Evaluate ability maximum SUV FDG-PET scan , obtain shortly SBRT , predict long-term local control time progression patient . - Evaluate ability peak SUV max SUV FDG-PET scan , obtain prior SBRT , predict local control time progression patient . - Determine utility PET/CT scan data guide treatment planning . - Determine treatment radiotherapy involve high biological dos limited treatment volume use SBRT technique achieve acceptable treatment-related toxicity . OUTLINE : This phase I dose-escalation study follow phase II open-label study . - Phase I : Patients undergo hypofractionated stereotactic body radiotherapy ( SBRT ) 3 time within 2-week time frame . Cohorts 3-6 patient receive escalate dos hypofractionated SBRT maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Phase II : Patients undergo hypofractionated SBRT MTD phase I . In phase , patient undergo fludeoxyglucose F 18-PET/CT scan baseline 12-16 week completion SBRT . After completion study treatment , patient follow periodically 4 year . PROJECTED ACCRUAL : A total 90 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage I II nonsmall cell lung cancer meeting follow criterion : No bronchoalveolar cell carcinoma Maximum T2 T3 tumor size ≤ 5 cm T3 primary tumor must limit chest wall Primary tumor T stage must within touch zone trachea proximal bronchial tree , define volume 2 cm direction around trachea proximal bronchial tree ( carina , right leave main bronchus , right leave upper lobe bronchus , intermedius bronchus , right middle lobe bronchus , right leave low lobe bronchus ) For lesion inferior proximal bronchial tree , primary tumor must within 2 cm esophagus Patients N1 ( hilar ) lymph node positive malignancy base size , fludeoxyglucose F 18 ( FDG ) PET scan uptake , biopsy eligible N1 lymph node locate contiguously within stereotactic radiation treatment field primary tumor Mediastinal lymph node must ≤ 1 cm abnormal uptake FDGPET scan area Patients &gt; 1 cm lymph node abnormal FDGPET scan ( include suspicious nondiagnostic uptake ) eligible direct tissue biopsy abnormally identify area negative cancer No evidence distant metastasis Suspected M1 disease base pretreatment PET imaging must biopsied If biopsy positive , patient ineligible If biopsy negative representative lesion question , patient eligible If biopsy nondiagnostic , consideration give repeat biopsy If repeat biopsy remain nondiagnostic biopsy feasible , patient ineligible Technically resectable disease Surgery refuse patient deem medically inoperable due comorbid condition PATIENT CHARACTERISTICS : Zubrod performance status 02 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No synchronous primary invasive malignancy within past 2 year nonmelanomatous skin cancer No active systemic , pulmonary , pericardial infection PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior chest radiotherapy ( lung mediastinum ) No concurrent anticancer therapy , include radiotherapy , radiofrequency ablation ( antineoplastic interventional radiology technique ) , chemotherapy , biological therapy , vaccine therapy , surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
</DOC>